Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
55 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014', provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6 Therapeutics Development 7 Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7 Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 12 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 13 INSYS Therapeutics, Inc. 13 Neotropix, Inc. 14 Novartis AG 15 Orphagen Pharmaceuticals, Inc. 16 Pfizer Inc. 17 Tekmira Pharmaceuticals Corp. 18 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ATR-101 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 axitinib - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 cintredekin besudotox - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 dovitinib lactate - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 NTX-010 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 TKM-PLK1 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates 43 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 49 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 50 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 51 Featured News & Press Releases 51 Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 51 Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 51 Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 55 Disclaimer 55
List of Tables Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2014 7 Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by INSYS Therapeutics, Inc., H2 2014 13 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Neotropix, Inc., H2 2014 14 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Novartis AG, H2 2014 15 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 16 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Pfizer Inc., H2 2014 17 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Recent Pipeline Updates, H2 2014 43 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2014 49 Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2014 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.